DE60230868D1 - Criptoblockierende antikörper und deren verwendung - Google Patents

Criptoblockierende antikörper und deren verwendung

Info

Publication number
DE60230868D1
DE60230868D1 DE60230868T DE60230868T DE60230868D1 DE 60230868 D1 DE60230868 D1 DE 60230868D1 DE 60230868 T DE60230868 T DE 60230868T DE 60230868 T DE60230868 T DE 60230868T DE 60230868 D1 DE60230868 D1 DE 60230868D1
Authority
DE
Germany
Prior art keywords
criptoblocking
antibodies
criptoblocking antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60230868T
Other languages
English (en)
Inventor
Michele Sanicola-Nadel
Kevin Williams
Susan Schiffer
Paul Rayhorn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27501437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60230868(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Inc filed Critical Biogen Inc
Application granted granted Critical
Publication of DE60230868D1 publication Critical patent/DE60230868D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
DE60230868T 2001-04-26 2002-04-17 Criptoblockierende antikörper und deren verwendung Expired - Lifetime DE60230868D1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28678201P 2001-04-26 2001-04-26
US29302001P 2001-05-17 2001-05-17
US30109101P 2001-06-26 2001-06-26
US36700202P 2002-03-22 2002-03-22
PCT/US2002/011950 WO2002088170A2 (en) 2001-04-26 2002-04-17 Cripto blocking antibodies and uses thereof

Publications (1)

Publication Number Publication Date
DE60230868D1 true DE60230868D1 (de) 2009-03-05

Family

ID=27501437

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60230868T Expired - Lifetime DE60230868D1 (de) 2001-04-26 2002-04-17 Criptoblockierende antikörper und deren verwendung

Country Status (34)

Country Link
US (6) US7531174B2 (de)
EP (3) EP2316486A3 (de)
JP (4) JP4307845B2 (de)
KR (1) KR100592357B1 (de)
CN (1) CN100352501C (de)
AR (3) AR037223A1 (de)
AT (2) ATE533508T1 (de)
BG (1) BG108363A (de)
BR (1) BR0209254A (de)
CA (2) CA2443840C (de)
CL (1) CL2009002199A1 (de)
CY (1) CY1108960T1 (de)
CZ (1) CZ20033208A3 (de)
DE (1) DE60230868D1 (de)
DK (1) DK1390389T3 (de)
EA (1) EA007469B1 (de)
EE (1) EE200300528A (de)
ES (1) ES2321065T3 (de)
GE (1) GEP20074091B (de)
HK (1) HK1058935A1 (de)
HU (1) HUP0501113A3 (de)
IS (1) IS2662B (de)
MX (1) MXPA03009797A (de)
MY (2) MY150237A (de)
NO (1) NO20034805L (de)
NZ (1) NZ566268A (de)
PL (1) PL207087B1 (de)
PT (1) PT1390389E (de)
RS (2) RS20110024A (de)
SG (1) SG157951A1 (de)
SI (1) SI1390389T1 (de)
SK (1) SK14432003A3 (de)
TR (1) TR200301846T2 (de)
WO (1) WO2002088170A2 (de)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR395801A0 (en) 2001-03-26 2001-04-26 Austin Research Institute, The Antibodies against cancer
US20090123470A1 (en) * 2001-03-26 2009-05-14 The Macfarlane Burnet Istitute For Medical Research And Public Health Ltd. Antibodies Against Cancer
JP4307845B2 (ja) 2001-04-26 2009-08-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｃｒｉｐｔｏをブロックする抗体およびその使用
US7582299B2 (en) 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
WO2003083041A2 (en) * 2002-03-22 2003-10-09 Biogen, Inc. Cripto-specific antibodies
CA2529945A1 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
CA2539116C (en) * 2003-09-15 2014-11-18 Research Development Foundation Cripto antagonism of activin and tgf-b signaling
CA2543888C (en) 2003-11-06 2016-01-19 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
AU2006203889A1 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. CRIPTO binding molecules
US20100105610A1 (en) * 2006-07-28 2010-04-29 Children's Memorial Hospital Methods of Inhibiting Tumor Cell Aggressiveness Using the Microenvironment of Human Embryonic Stem Cells
WO2008150530A2 (en) * 2007-06-01 2008-12-11 Biogen Idec Ma Inc. Cripto binding molecules
WO2009131852A1 (en) * 2008-04-21 2009-10-29 Merck & Co., Inc. Pancreatic beta-cell mass biomarker
CN102272157B (zh) * 2008-11-07 2015-11-25 研究发展基金会 用于抑制cripto/grp78复合物形成和信号的组合物和方法
IN2012DN03025A (de) 2009-09-09 2015-07-31 Ct Se Llc
US20130028917A1 (en) 2010-04-15 2013-01-31 Spirogen Developments Sàrl Pyrrolobenzodiazepines and conjugates thereof
US9000130B2 (en) 2010-06-08 2015-04-07 Genentech, Inc. Cysteine engineered antibodies and conjugates
CN103313990B (zh) 2010-11-17 2016-07-20 基因泰克公司 丙氨酰美登醇抗体偶联物
CA2830349C (en) 2011-03-17 2019-07-16 The University Of Birmingham Re-directed immunotherapy
BR112013027119A8 (pt) 2011-04-21 2018-03-06 Seattle Genetics Inc novos conjugados ligante-droga (adcs) e uso dos mesmos
WO2012155019A1 (en) 2011-05-12 2012-11-15 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
CA2850371C (en) 2011-10-14 2020-06-30 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
DK2906253T3 (en) 2012-10-12 2018-10-22 Adc Therapeutics Sa Pyrrolobenzodiazepine anti-PSMA antibody conjugates
KR101995620B1 (ko) 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항체 컨주게이트
LT2906251T (lt) 2012-10-12 2017-12-11 Adc Therapeutics Sa Pirolobenzodiazepino-anti-cd22 antikūno konjugatai
PT2766048E (pt) 2012-10-12 2015-02-25 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
ES2660029T3 (es) 2012-10-12 2018-03-20 Medimmune Limited Conjugados de anticuerpo-pirrolobenzodiazepinas
CA2887895C (en) 2012-10-12 2019-10-29 Adc Therapeutics Sarl Pyrrolobenzodiazepine-anti-cd19 antibody conjugates
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
EP2935273A1 (de) 2012-12-21 2015-10-28 MedImmune Limited Asymmetrische pyrrolobenzodiazepin-dimere zur verwendung bei der behandlung von proliferativen und autoimmunerkrankungen
CN110452242A (zh) 2012-12-21 2019-11-15 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
MX364330B (es) 2013-03-13 2019-04-23 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
CA2905181C (en) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy
AR096287A1 (es) 2013-03-13 2015-12-23 Spirogen Sàrl Pirrolobenzodiacepinas y conjugados
TWI636792B (zh) 2013-08-12 2018-10-01 建南德克公司 １－（氯甲基）－２，３－二氫－１ｈ－苯并［ｅ］吲哚二聚體抗體－藥物結合物化合物及使用與治療方法
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054985B1 (de) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepin-antikörper-konjugate
WO2015052532A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
CA2928952A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
BR112016013258A2 (pt) 2013-12-16 2018-01-16 Genentech Inc composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit
WO2015095227A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
NZ720736A (en) 2013-12-23 2020-08-28 Bayer Pharma AG Antibody drug conjugates (adcs) with kinesin spindel protein (ksp)
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP3388449A3 (de) 2014-09-12 2018-10-24 F. Hoffmann-La Roche AG Cystein-manipulierte antikörper und konjugate
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CR20170099A (es) 2014-09-17 2017-07-19 Genentech Inc Pirrolobenzodiazepinas y conjugados de anticuerpos-disulfuro de las mismas
AU2015352545B2 (en) 2014-11-25 2020-10-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CA2969689A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
US20180125936A1 (en) * 2015-04-07 2018-05-10 Paranta Biosciences Limited Method of treating neoplasias
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
CA2990076A1 (en) 2015-06-22 2016-12-29 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN116059390A (zh) 2016-03-24 2023-05-05 拜耳制药股份公司 具有酶促可裂解基团的细胞毒性活性物质的前药
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
ES2858151T3 (es) 2016-05-20 2021-09-29 Hoffmann La Roche Conjugados de PROTAC-anticuerpo y procedimientos de uso
EP3465221B1 (de) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytisches verfahren zur charakterisierung von ortsspezifischen antikörper-wirkstoff-konjugaten
EP3464280B1 (de) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol-antikörper-arzneimittelkonjugate und verfahren zur verwendung
JP7022707B2 (ja) 2016-06-15 2022-02-18 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤および抗ｃｄ１２３抗体を含む特異的抗体－薬物－コンジュゲート（ａｄｃ）
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
BR112019012883A2 (pt) 2016-12-21 2019-11-26 Bayer Ag conjugados de ligante-fármaco (adcs) que têm grupos enzimaticamente cliváveis
KR20190099250A (ko) 2016-12-21 2019-08-26 바이엘 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물
US11433140B2 (en) 2016-12-21 2022-09-06 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (ADCs) having KSP inhibitors
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
EP3544636B1 (de) 2017-02-08 2021-03-31 ADC Therapeutics SA Pyrrolobenzodiazepin-antikörper-konjugate
PL3612537T3 (pl) 2017-04-18 2022-11-07 Medimmune Limited Koniugaty pirolobenzodiazepin
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
EP3638373A1 (de) 2017-06-14 2020-04-22 ADC Therapeutics SA Dosierungsschemata zur verabreichung eines anti-cd19-adc
EP3668874B1 (de) 2017-08-18 2021-12-22 Medimmune Limited Pyrrolobenzodiazepinkonjugate
AU2018337815A1 (en) 2017-09-20 2020-03-12 Ph Pharma Co., Ltd. Thailanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
JP7390315B2 (ja) 2018-06-01 2023-12-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 スプライシング調節薬抗体－薬物コンジュゲート及びその使用方法
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
CA3115110A1 (en) 2018-10-24 2020-04-30 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
JP2022512401A (ja) 2018-12-13 2022-02-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハーボキシジエンスプライシング調節薬抗体－薬物コンジュゲート及びその使用方法
KR20210105890A (ko) 2018-12-17 2021-08-27 레비토프 리미티드 트윈 면역 세포 인게이저
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) * 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5780029A (en) 1989-11-14 1998-07-14 New York Medical College Antidiotypic monoclonal antibodies for treatment of melanoma
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5264557A (en) 1991-08-23 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Polypeptide of a human cripto-related gene, CR-3
US6063379A (en) 1993-12-09 2000-05-16 Centro De Inmunologia Molecular Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies
US5981215A (en) * 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
US6207153B1 (en) * 1996-05-22 2001-03-27 Viventia Biotech, Inc. Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
DK2112166T3 (en) 1998-12-23 2019-02-04 Pfizer Human monoclonal antibodies to CTLA-4
WO2000052204A2 (en) 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
CA2368734C (en) 1999-03-30 2005-08-23 Japan Tobacco Inc. Method for preparing monoclonal antibody
CA2370760A1 (en) * 1999-04-20 2000-10-26 William J. Kokolus Improved method of identifying and locating immunobiologically-active linear peptides
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
JP2001046066A (ja) 1999-08-03 2001-02-20 Kyowa Hakko Kogyo Co Ltd 新規な相補性決定領域を有するヒトｖｅｇｆ受容体ｋｄｒに対する抗体
JP4028237B2 (ja) 1999-10-29 2007-12-26 ジェネンテック・インコーポレーテッド 抗前立腺幹細胞抗原（ｐｓｃａ）抗体組成物及び使用方法
US6663613B1 (en) 2000-01-25 2003-12-16 Bacchus Vascular, Inc. System and methods for clot dissolution
PT1270595E (pt) * 2000-03-03 2008-09-16 Kyowa Hakko Kogyo Kk Anticorpo recombinante de genes e os seus fragmentos
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
GB0020953D0 (en) 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
NZ525380A (en) * 2000-09-18 2008-06-30 Biogen Idec Inc Non-fucosylated forms of Cripto and their use as tumor blocking agents
AU2002236871B2 (en) 2001-01-26 2006-09-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Detection and quantification of CRIPTO-1
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
CN1494553A (zh) 2001-01-29 2004-05-05 IDECҩ�﹫˾ 改变的抗体及其使用方法
AUPR395801A0 (en) 2001-03-26 2001-04-26 Austin Research Institute, The Antibodies against cancer
JP4307845B2 (ja) 2001-04-26 2009-08-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｃｒｉｐｔｏをブロックする抗体およびその使用
WO2003083041A2 (en) * 2002-03-22 2003-10-09 Biogen, Inc. Cripto-specific antibodies
US7582299B2 (en) * 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
EP2174953A1 (de) * 2001-09-18 2010-04-14 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
US20040014690A1 (en) 2002-02-13 2004-01-22 Zhenkun Ma Macrolides with activity against methicillin-resistant staphylococcus aureus
CA2539116C (en) * 2003-09-15 2014-11-18 Research Development Foundation Cripto antagonism of activin and tgf-b signaling
AU2006203889A1 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. CRIPTO binding molecules
CN101479391A (zh) 2006-04-28 2009-07-08 比奥根艾迪克Ma公司 用于检测cripto-3的组合物及方法

Also Published As

Publication number Publication date
CZ20033208A3 (en) 2004-03-17
SI1390389T1 (sl) 2009-06-30
MXPA03009797A (es) 2004-01-29
MY150237A (en) 2013-12-31
AR072554A2 (es) 2010-09-08
TR200301846T2 (tr) 2006-10-26
US20080166341A1 (en) 2008-07-10
EP1390389B1 (de) 2009-01-14
EP1390389A2 (de) 2004-02-25
YU84903A (sh) 2006-05-25
ATE533508T1 (de) 2011-12-15
US20120195912A1 (en) 2012-08-02
HUP0501113A2 (en) 2007-05-02
DK1390389T3 (da) 2009-04-20
HK1058935A1 (en) 2004-06-11
NO20034805D0 (no) 2003-10-27
JP4307845B2 (ja) 2009-08-05
PT1390389E (pt) 2009-04-03
EP1390389A4 (de) 2004-09-22
AR077759A2 (es) 2011-09-21
ATE420659T1 (de) 2009-01-15
EA200301158A1 (ru) 2005-06-30
US8673303B2 (en) 2014-03-18
KR100592357B1 (ko) 2006-06-22
US8003763B2 (en) 2011-08-23
CN100352501C (zh) 2007-12-05
CN1606453A (zh) 2005-04-13
RS51635B (sr) 2011-08-31
ES2321065T3 (es) 2009-06-02
WO2002088170A2 (en) 2002-11-07
BG108363A (bg) 2004-09-30
KR20040028744A (ko) 2004-04-03
CA2443840C (en) 2010-10-26
CA2715570A1 (en) 2002-11-07
AR037223A1 (es) 2004-11-03
GEP20074091B (en) 2007-04-25
US20090285818A1 (en) 2009-11-19
CY1108960T1 (el) 2014-07-02
EP1974749A1 (de) 2008-10-01
IS6999A (is) 2003-10-24
SK14432003A3 (sk) 2004-07-07
US7888052B2 (en) 2011-02-15
EP1974749B1 (de) 2011-11-16
US20090286265A1 (en) 2009-11-19
EP2316486A3 (de) 2011-09-07
US20100202962A1 (en) 2010-08-12
SG157951A1 (en) 2010-01-29
BR0209254A (pt) 2006-10-03
IS2662B (is) 2010-08-15
NZ566268A (en) 2009-09-25
NO20034805L (no) 2003-12-23
US7531174B2 (en) 2009-05-12
PL373513A1 (en) 2005-09-05
JP2010163438A (ja) 2010-07-29
JP4575983B2 (ja) 2010-11-04
MY157382A (en) 2016-06-15
EA007469B1 (ru) 2006-10-27
JP2004534020A (ja) 2004-11-11
CL2009002199A1 (es) 2010-05-07
WO2002088170A3 (en) 2003-12-24
HUP0501113A3 (en) 2007-12-28
EE200300528A (et) 2004-08-16
JP2009108100A (ja) 2009-05-21
US7674462B2 (en) 2010-03-09
JP2005314436A (ja) 2005-11-10
US20040146940A1 (en) 2004-07-29
EP2316486A2 (de) 2011-05-04
RS20110024A (en) 2011-08-31
CA2443840A1 (en) 2002-11-07
PL207087B1 (pl) 2010-10-29

Similar Documents

Publication Publication Date Title
DE60230868D1 (de) Criptoblockierende antikörper und deren verwendung
ATE412013T1 (de) Anti-osteopontin-antikörper und dessen verwendung
DE60105859D1 (de) Urazil Verbindungen und deren Verwendung
ATE470675T1 (de) Immunoglobulinvarianten und deren verwendungen
DE60039589D1 (de) Rekombinante il-18 antikörper und deren verwendung
DE50115561D1 (de) Spektralphotometer und Verwendung desselben
ATE271066T1 (de) Lösliche mutante ctla4 moleküle und deren verwendung
ATE424202T1 (de) Substituierte 2-thio-3,5-dicyano-4-phenyl-6- aminopyridine und ihre verwendung
DE602004021904D1 (de) Gyraseinhibitoren und deren verwendungen
DE60238894D1 (de) Beleuchtungssystem und dessen Verwendung in Projektionssystem
DE60208351D1 (de) Glukopyranosyloxybenzylbenzolderivate und deren medizinische verwendung
DE60230591D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
DE60237580D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
ATE458717T1 (de) Beta-amino-alpha-cyanoacrylate und deren verwendung als herbizide
DE50111690D1 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
ATE435872T1 (de) Anti-interleukin-1 rezeptor antikörper und deren verwendung
DE60235547D1 (de) En daraus, deren herstellung und verwendung
DE60216345D1 (de) Gummimischung und deren Verwendung
DE60230245D1 (de) Wabenkonstruktion und deren zusammenbau
ATE364575T1 (de) Zeolithe und deren verwendung
DE50206094D1 (de) Substituierte isoindole und ihre verwendung
ATE300525T1 (de) Uracilverbindungen und deren verwendung
DE50214357D1 (de) Zahnradpaarung und deren Verwendung
DE50008549D1 (de) Triazolotriazinone und ihre verwendung
DE60216376D1 (de) Verbundklebstoff und dessen Verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition